Clinical Trial

Study on Variation of Serum and Fecal Biomarkers After Treatment to Predict Mucosal Healing in Patients With Ulcerative Colitis

Study acronym: MIROIR

Terminated

View on ClinicalTrials.gov →

Why the trial stopped

We were able to test our hypothesis using the current data

Summary

Mucosal healing is recognized hitherto as the best therapeutic endpoint in patients with Ulcerative Colitis (UC) but its use in daily practice is limited by the low acceptability of repeated colonoscopies. In this context, fecal biomarkers are attractive alternatives. Fecal calprotectin showed very good negative predictive value to eliminate IBD diagnosis, good correlation to endoscopic activity and good ability to predict relapse. Recently, several teams including ours, showed that fecal biomarkers such as Chitinase 3-Like 1 (CHI3L1), matrix metalloprotease type 9 (MMP-9) and serum biomarkers neutrophil gelatinase B- complex associated lipocalin (NGAL)-MMP9 and serum CHI3L1 could be better biomarkers than fecal calprotectin to assess endoscopic activity in patients with UC.

Trial Details

NCT Number	NCT07653750
Lead Sponsor	University Hospital, Clermont-Ferrand
Conditions	Moderate to Severe Ulcerative Colitis
Enrollment	62 participants
Start Date	2021-06-25
Primary Completion	2026-06-09 (estimated)
Study Completion	2026-06-09 (estimated)
Updated on ClinicalTrials.gov	2026-06-17